Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 11-12/2002

01-12-2002 | Original Article

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

Authors: Gerard Groenewegen, Andries Bloem, Gijsbert C. de Gast

Published in: Cancer Immunology, Immunotherapy | Issue 11-12/2002

Login to get access
Metadata
Title
Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha
Authors
Gerard Groenewegen
Andries Bloem
Gijsbert C. de Gast
Publication date
01-12-2002
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 11-12/2002
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-002-0323-1

Other articles of this Issue 11-12/2002

Cancer Immunology, Immunotherapy 11-12/2002 Go to the issue

Original Article

Linomide administration following bone marrow transplantation in mice

Original Article

Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical phase I/II trial

Original Article

Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination

Original Article

Efficient carcinoma cell killing by activated polymorphonuclear neutrophils targeted with an Ep-CAM×CD64 (HEA125×197) bispecific antibody

Review

Adjuvant immunotherapy for solid tumors: from promise to clinical application

Original Article

Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I/II clinical trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits